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Abstract: Currently, the post-remission treatment in acute leukemia is based on the genetic 
profile of leukemic cells at diagnosis (ie, FLT3 ITD positivity) and on the level of measur-
able residual disease (MRD) after induction and consolidation chemotherapy. Two methods 
are currently preferred for MRD evaluation in many centers: multiparameter flow cytometry 
and real-time quantitative PCR. Additional methods such as next-generation sequencing 
and digital PCR are under investigation, in an attempt to increase the sensitivity and thus 
allowing the detection of small clones. Many studies suggest that MRD positivity after 
chemotherapy is associated with negative prognosis, and the reappearance of MRD during 
follow-up allows impending relapse to be identified and consequently enables early inter-
vention. Finally, MRD positivity before hematopoietic stem cell transplantation is predic-
tive of the outcome. Although the significance of MRD in acute leukemia has been widely 
explored, the assessment of molecular MRD is not yet a routine practice. In this review, we 
describe the significance of MRD in different settings and the main markers and methods 
used for MRD detection.
Keywords: minimal residual disease, acute leukemia, multiparameter flow cytometry, real-time 
quantitative polymerase chain reaction, next-generation sequencing, digital PCR
Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of clonal hematopoietic stem 
cell disorders with different sensitivity to chemotherapy.1 The molecular pathogenesis 
of AML has been studied for years by cytogenetic and molecular analyses.1,2 Recurrent 
genetic abnormalities play an essential role in the pathogenesis of the disease and are 
well established prognostic markers. More recently, studies based on next-generation 
sequencing (NGS) clearly showed that leukemia is composed of different clones having 
different genetic profiles.2,3 Frequently, a funding clone can be identified at diagnosis 
and additional small subclones can be detected only by very sensitive methods.4,5 
The small clones, undetectable at diagnosis, are capable of expansion over time and 
might be responsible for relapse. Furthermore, additional mutations may emerge in 
clones and subclones during chemotherapy and may change their sensitivity profile 
to different agents, thus favoring chemo-resistance and finally relapse.4 The so-called 
“clonal evolution” explains the different mutational profiles frequently observed from 
diagnosis to relapse.
Although the majority of patients with de novo AML can undergo morphologi-
cal remission after chemotherapy treatment, the rate of relapse is still very high.1 A 
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number of studies clearly showed that the identification of 
persistence of a small amount of minimal residual disease, 
or more precisely measurable residual disease (MRD), is an 
important prognostic factor to establish the risk of relapse 
and, as a consequence, the post-remission therapy.6,7
Currently, the post-remission treatment is based on the 
genetic profile of leukemic cells at diagnosis and on the 
level of minimal residual disease after induction and con-
solidation chemotherapy, detected by multiparameter flow 
cytometry (MFC) in the majority of the studies.8 In this 
review, an example is provided by the GIMEMA clinical trial 
AML1310 (ClinicalTrials.gov. Identifier NCT01452646) that 
stratified the post-remission therapy according to the pres-
ence of MRD. Intermediate-risk AML with positive MRD 
received allogeneic hematopoietic stem cell transplantation 
(allo-HSCT), while MRD-negative cases were treated only 
with consolidation chemotherapy. Although the results are 
still under analysis, it is reasonable that in the near future 
the decision between chemotherapy or chemotherapy plus 
allo-HSCT will be based not only on genetic risk at diagnosis 
but also on the presence of MRD.
The reappearance of MRD during follow-up allows iden-
tification of  identify impending relapse and consequently 
enables early intervention.7
Despite the significance of MRD in acute leukemia having 
been widely explored, with an increasing number of studies 
demonstrating the positive prognostic value of MRD nega-
tivity, the assessment of molecular minimal residual disease 
is not yet a routine practice. Many studies are based on few 
genetic markers and the agreement on the methods and targets 
is still far from being reached. An attempt to standardize the 
methodology and to provide suggestion on when and how to 
monitor MRD has been recently published under the aegis 
of the European Leukemia Net (ELN).9
MRD indicates the presence of leukemia cells down to 
the levels of 1:104 to 1:106 white blood cells, compared with 
1:20 in morphology-based measurement.
Two methods are currently preferred for MRD evalua-
tion in many centers: MFC and real-time quantitative PCR 
(qPCR). Additional methods such as NGS and droplet digi-
tal PCR (ddPCR) are under investigation, in an attempt to 
increase the sensitivity and thus allow the detection of small 
clones. Each methodology differs in the sensitivity to detect 
the presence of MRD and in the number of patients who can 
potentially be monitored.
When applying molecular monitoring in AML patients, 
an important aspect should be considered, ie, the age-related 
clonal hematopoiesis. In the last few years, at least three 
different large studies carried out on thousands of healthy 
subjects of different ages investigated the presence of muta-
tions in hematopoietic cells by using NGS technique.10–12 The 
mutations detected in healthy subjects are typical of leukemic 
cells including TET2, DNMT3A, and ASXL1. These studies 
identified mutations with an allele frequency of more than 2% 
in an increasing proportion of subjects during aging. By the 
age of 70 years, more than 10% of the subjects have clonal 
hematopoiesis which is a risk factor for both the development 
of malignancies, which occur in 0.5%–1% of them per year, 
and cardiovascular events, with an increased risk of four 
times compared to age-matched controls.11,12 The detection 
of mutations in healthy people suggests the existence of pre-
leukemic stem cells. When additional mutations are acquired, 
leukemia might develop. Intensive chemotherapy selectively 
targets the malignant clone, thus allowing the pre-leukemic 
clone to survive.
Recently, the persistence of these mutations has been 
demonstrated during remission after chemotherapy without 
an evident impact on relapse, suggesting the persistence 
of pre-leukemic stem cells.5 These data have an important 
impact on the significance of MRD and on the choice of the 
molecular marker to follow.
Molecular MRD
There are two main approaches for molecular MRD quan-
tification: real-time PCR and DNA sequencing.9 The PCR 
approach includes real-time PCR, digital PCR, and chime-
rism analysis. Real-time PCR represents, so far, the gold stan-
dard for MRD detection, although its application is limited 
to a selected number of patients (about 40%), carrying one 
or more suitable molecular markers.13
This limitation might be overcome by NGS that, at least in 
theory, can be applied to all leukemia-specific genetic mark-
ers. This approach can increase the percentage of patients who 
can be monitored by another 40%. However, this method still 
requires validation and standardization.9
Marker for molecular MRD
Fusion transcript in core binding factor (CBF) 
leukemias: CBFB-MYH11 and RUNX1-RUNX1T1
Despite the negative impact of MRD positivity in core bind-
ing factor (CBF) leukemias on relapse, no effect was clearly 
demonstrated on overall survival (OS) in multivariate analysis. 
This could be ascribed to the relatively high response rates of 
CBF leukemias to salvage therapy. In inv(16) patients, Yin et al14 
demonstrated that after induction chemotherapy, more than ten 
CBFB-MYH11 copies /105 ABL copies in peripheral blood were 
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the most useful prognostic variables for relapse risk on multi-
variate analysis. MRD, after the end of therapy, was also infor-
mative with levels of transcript inferior to ten copies/105ABL 
copies in peripheral blood (PB) associated with a cumulative 
incidence of relapse at 5 years in 36% of cases compared to 
78% for those not reaching this threshold. During follow-up, 
the presence of less than 50 copies/105ABL copies of transcript 
in bone marrow (BM) and ten copies in PB was associated with 
an OS at 5 years of 100% and 91%, respectively.14 We should 
therefore keep in mind that low and stable levels of transcripts 
may be detectable by PCR for a relatively long period of time 
after chemotherapy without evidence of relapse.15
Similarly, for RUNX1-RUNX1T1, Yin et al15 established 
that a threshold of less than 100 copies/105 ABL copies in PB 
and less than 500 copies /105 ABL copies in BM was associ-
ated with an OS at 5 years of 95% and 94%, respectively. 
The French group16 analyzed 94 RUNX1-RUNX1T1 positive 
patients during follow-up and showed that the molecular 
remission after the completion of consolidation therapy was 
not predictive. By contrast, the negativity in PB at the same 
time point predicts an OS at 4 years of 96% compared to 
63% if positive. As for CBFB- MYH11, the MRD negativity 
at earlier time was not prognostically relevant.16
NPM1 mutation
The mutation of NPM1 can be target for MRD by qPCR. 
NPM1 has been found to be mutated in 50%–60% of AML 
patients with a normal karyotype.21
The presence of measurable NPM1 transcripts in PB or 
in BM after at least two cycles of chemotherapy is associ-
ated with a high risk of relapse in many studies.20 Ivey et al17 
reported a 3-year OS of 75% for patients with NPM1 negativity 
in PB vs 24% for those with positive NPM1. Shayegi et al18 
reported a 3-year OS of 84% for negative patients at the same 
time point but measured in BM compared to 76% for those 
with low NPM1 levels (NPM1/ABL <1%) and 45% with those 
who maintain positive levels with a NPM1/ABL ratio >1%. 
Similarly, Kronke et al19 reported a 4-year OS of 90% for those 
who reached NPM1 negativity in BM after two cycles of che-
motherapy compared to 56% for those with NPM1 positivity.
For patients who obtain a NPM1 negativity in PB but 
remain positive in BM after the end of treatment, the ELN 
recommendations suggest to closely monitor the mutation in 
PB and BM every 4 weeks for at least 3 months.9
PML-RARA
In acute promyelocytic leukemia, the most significant MRD 
end point is the achievement of PCR negativity for PML-
RARA at the end of consolidation treatment, independently 
from the therapeutic strategy, all-trans retinoic acid (ATRA) 
associated with chemotherapy, or ATRA and arsenic trioxide. 
PML-RARA negativity at the end of consolidation treatment 
is associated with a low risk of relapse and a high probability 
of long-term survival.22,23
As for CBF leukemia, we should consider that measur-
able levels of PML-RARA during active treatment should 
not trigger a treatment change. The usefulness of serial 
PCR-based MRD monitoring during treatment is still under 
investigation.
The wilms’ tumor gene (wT1)
The usefulness of WT1 quantitative assessment, using 
q-PCR, as a marker for MRD detection in AML has been 
demonstrated many years ago.24–30 WT1 is overexpressed 
in about 80%–90% of the patients.24,25 The persistence of 
WT1 overexpression after treatment is always indicative of 
MRD.24–30 WT1 can thus be considered as the most universal 
marker of AML. In a European study, it was shown that both 
the level of WT1 reduction from baseline after induction or 
consolidation therapy and the clearance of the transcript to 
normal values are highly predictive of relapse.25 Many stud-
ies suggested that the persistence of abnormal values of WT1 
after induction or consolidation treatment has an impact on 
the probability of relapse. An increase of WT1 levels during 
follow-up always predicts the leukemia recurrence.
Importantly, WT1 is overexpressed independently of the 
genetic lesion(s) in the leukemic cells. This could generate 
suspicion because it is evident that WT1 is not specific for one 
particular leukemic clone. By contrast, considering the recent 
advances coming from NGS studies that clearly indicate that 
there is a clonal selection in acute leukemias, the usefulness 
of a molecular marker able to track all the leukemic clones 
independently from all genetic lesions is unquestionable.
The main advantages of WT1 assay are that it can be 
measured in PB, the method has been standardized,25 the 
assessment of the results is not dependent on human exper-
tise, in contrast to flow cytometric analysis of MRD, and it can 
detect the emergence of leukemic clones that are genetically 
or phenotypically different from those detected at diagnosis.
In the recent recommendations of the ELN by Schuurhuis 
et al,9 the authors claimed that WT1 mRNA quantitation 
should not be used as minimal residual disease marker in 
AML, due to low sensitivity and specificity, unless no other 
MRD markers, including flow cytometric ones, are available 
in the patient. Despite these recommendations, in the last 15 
years, many scientific papers have been published showing 
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that WT1 is a reliable marker of MRD that is able to predict 
relapse with a high level of accuracy.24–30
The fear of the lack of WT1 sensitivity is mainly based on 
the fact that there is a background of expression in healthy 
subjects.25 In addition, the absolute value of WT1 in AML 
at diagnosis is not always two logs higher than in normal 
samples.28 This led to a sort of skepticism toward WT1 that, 
however, cannot be justified by the evidence provided by 
prospective and retrospective studies.24,25,28
Additional molecular markers
BCR-ABL
The 2016 WHO diagnostic guidelines included BCR-ABL 
positive trait as a provisional entity. The vast majority of 
the patients are characterized by p190 transcript, which is 
uncommon in chronic myeloid leukemia patients.31
Since BCR-ABL positive AML is a rare subtype of leu-
kemia, very little data are available on the outcome and the 
prognostic value of BCR-ABL-based MRD detection.
iDH1/iDH2
Since the evidence that IDH1/IDH2 genes can be mutated 
in about 10%–20% of AML cases, many groups are investi-
gating the possibility of using IDH1/2 as a marker for MRD 
detection.
Until now, it is not clear whether IDH1/IDH2 become 
negative during remission, and contrasting data are reported 
in literature.32,33 There are studies reporting the stability and 
suitability of IDH as a marker of MRD.32,34 Recently, Petrova 
t al35 published the evaluation of MRD in 90 patients, 22% of 
them with IDH1/IDH2 mutations. They based the assessment 
on NGS and ddPCR. Many patients presented additional 
mutations such as NPM1 or MLL-PDT and this allowed clini-
cians to conclude that IDH1/2 correlated with the treatment 
response. Despite this, they found that the approach based on 
IDH1/2 is less sensitive than NPM1 in predicting relapse but 
more sensitive than MLL-partial tandem duplication (PTD).
Brambati et al explored the possibility of detecting 
IDH1/2 after transplantation to better identify the risk of 
relapse.34 They concluded that longitudinal monitoring of 
these mutations can be extremely useful in the allo-trans-
plantation setting, a context in which these alterations can 
be considered markers of undesired residual pre-leukemic 
host hematopoiesis.
Multiparameter flow cytometry
Lots of effort has been devoted in an attempt to obtain the 
standardization of MFC.36 For years, the detection of the 
leukemic population has been based on a panel of antibodies 
targeting early markers such as CD34 and CD117, markers 
of myeloid-lineage such as CD33, and myeloid differentia-
tion antigens like CD11b, CD13, CD14, CD15 or lymphoid 
antigens including CD2, CD7, CD19, or CD56.
Two different approaches have been used to measure 
MRD with MFC: the leukemia-associated immunophenotype 
(LAIP) approach which characterizes the LAIP at diagnosis 
and tracks the identified population of blast cells during 
follow-up.37 A second approach is based on “different from 
normal” approach (DfN), which is based on the identifica-
tion of aberrant differentiation/maturation profiles at any 
time point. The DfN approach has the advantage that it can 
be applied even in the absence of the immunophenotype 
at diagnosis and can detect the immunophenotype shifts,38 
which is caused by the appearance of new clones. Immuno-
phenotype shifts may emerge from leukemia evolution or 
clonal selection.39
The use of a large panel of antibodies can overcome the 
problem of using LAIP rather than DfN, as it is able to cover 
both the aspects.
Recently, the ELN recommendations suggest the term 
“LAIP-based DfN approach” for this combination strategy 
that can provide characterization of leukemic cells at diag-
nosis, MRD evaluation, and detection of new aberrancies 
not present at diagnosis.9 For all these reasons, the ELN 
researchers recommend to use at least eight colors.
Differently from what has been demonstrated for qPCR-
based MRD assessment, the evaluation of MRD by MFC is 
not recommended in PB for the lower frequency of leukemic 
cells.
Another important limitation of MFC was the absence 
of a commonly accepted threshold of negativity that is able 
to distinguish between MRD-positive and -negative cases. 
As 0.1% was found to be relevant in many published stud-
ies, the ELN recommends using this threshold. However, 
an MRD below 0.1 can be consistent with the persistence 
of residual leukemic cells. Several studies demonstrated the 
prognostic value of MRD to be below 0.01%,40,41 showing 
that this threshold can identify patients with a very good 
prognosis. Independent validation of these very low levels 
may be highly relevant in future.
MRD in the setting of allogeneic stem cell 
transplantation
Many published data support the notion that the presence of 
MRD immediately prior to allo-HSCT is a strong, indepen-
dent predictor of post-transplant outcomes in AML.42
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The MRD positivity has been defined as one of the 
stronger predictive factors both in the ablative and non-
myeloablative transplants.43
In a large study carried out in 279 AML patients, Zhou et 
al investigated MRD before and after HSCT.44 It was shown 
that patients with MRD positivity before transplantation have 
a high relapse risk regardless of whether or not they clear 
MRD with conditioning chemotherapy.44
Studies in NPM1-mutated patients confirmed the impact 
of MRD pre-transplantation on the OS.45 It was shown that 
only those patients who achieved at least a suboptimal reduc-
tion of NPM1 levels after chemotherapy showed an improved 
OS after HSCT.
Bill et al46 analyzed a cohort of 51 NPM1-mutated patients 
who received HSCT. Mutated NPM1 MRD-positive patients, 
measured by ddPCR, had higher cumulative incidence of 
relapse and shorter OS. They demonstrated that NPM1 MRD 
positivity, measured by ddPCR before allogeneic stem cell 
transplantation, is associated with worse prognosis indepen-
dent of other known prognostic markers. Similar results have 
been described by Kayser et al47 in a series of 67 patients. 
More recently, to extend the evaluation of MRD to all the 
patients treated with HSCT, an NGS approach has been 
used in a cohort of 116 patients in complete remission who 
were treated with HSCT.48 The MRD was measured before 
transplantation, and it was demonstrated, in multivariate 
analysis, that MRD positivity was an independent negative 
predictor of relapse.
Finally, many papers reported the value of WT1 moni-
toring in the setting of HSCT, both before HSCT to assess 
the quality of the remission and therefore predict the 
outcome and after HSCT to predict relapse.48–52 The data 
reported in this setting are quite strong and led several 
centers to adopt WT1-based pre-emptive immunotherapy 
with cyclosporine discontinuation and/or donor lympho-
cyte infusion in patients with increasing WT1 values after 
transplantation.53,54
Finally, although many studies reported that the CBFB-
MYH11 fusion transcript can persist at low level in patients 
during long-term remission after chemotherapy, only a few 
studies with small samples have addressed the detection of 
the CBFB-MYH11 fusion transcripts after allo-HSCT.55
More recently, Tang et al reported 53 high-risk adult AML 
patients with inv(16) who received allo-HSCT.56 During 
follow-up, seven patients experienced relapse. All relapses 
occurred in patients who either did not achieve major molecular 
response within the first 3 months or who lost major molecular 
response (MMR) in the first 3 months from transplantation.56
Digital PCR
New techniques are on the horizon for the detection of small 
leukemic clones. A promising approach is based on digital 
PCR. Digital PCR is a breakthrough technology designed 
to provide absolute nucleic acid quantification. It is particu-
larly useful in detecting low amounts of target; therefore, 
it is highly sensitive in detecting MRD. It is estimated that 
ddPCR can detect up to 0.001% mutated allele frequency.57
This technique can overcome some difficulties faced by 
conventional PCR. With ddPCR, a sample is partitioned in 
single nucleic acid molecules. As a result of the partition-
ing of the sample into some sort of “bubbles”, each bubble 
will contain zero or one molecule. After PCR amplification, 
nucleic acids may be quantified by counting the bubbles 
containing PCR end products. The main disadvantages for 
now are the cost of the analysis, the limited availability of the 
instruments that are not routinely introduced into diagnostic 
laboratories, and the lack of standardization.
In conventional PCR, the starting copy number is pro-
portional to the number of PCR amplification cycles. Digital 
PCR, however, is not dependent on the number of amplifica-
tion cycles to determine the initial sample amount, eliminat-
ing the reliance on uncertain exponential data to quantify 
target nucleic acids and providing absolute quantification.
Few studies have been published on MRD by  ddPCR. 
We have already mentioned the study by Petrova et al35 based 
on IDH1/2 mutation. This technique has also been explored 
by Brambati et al34 in the setting of allogeneic bone marrow 
transplantation to identify the reappearance of small mutated 
clones of the recipient. In the same setting, Bill et al46 reported 
the prognostic significance of NPM1 positivity by ddPCR. 
A new assay based on digital PCR technique composed of 
multiplex pools of insertion-specific primers that selectively 
detect mutated but not wild-type NPM1 has been described 
by Mencia-Trinchant et al.58
Next-generation sequencing
On the basis of the concept that MRD evaluation requires 
more than one technology and more than one marker, NGS 
is presently under investigation. Since there is a high degree 
of genotypic and phenotypic heterogeneity in AML, each 
patient should have a unique signature to be used to track 
MRD after therapy. Whole genome- or exome sequencing-
based identification of clones and subclones in patients at 
diagnosis allows MRD to be followed by individualized 
monitoring. The usefulness of an NGS-based MRD assay 
is not only the prognostic stratification for relapse risk but 
also for the identification of different drugable targets for a 
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personalized therapy.59 Prospective studies of the use of NGS 
in AML as a marker of MRD in the pre- and post-transplant 
setting are ongoing.
The main advantages of NGS technology are the reduced 
DNA sequencing time and cost, and the remarkably increased 
data-production capacity. NGS technologies rely on different 
methods for DNA template preparation, massively parallel 
reading of sequenced millions of short DNAs, real-time 
image capturing, alignment of sequences, sequence assembly, 
and variant detection. Each method has specific advantages: 
read length, accuracy, run time, and throughput. The main 
disadvantages of using NGS are shorter read length and the 
fact that its ability to detect MRD depends on the depth of 
sequencing and on the type of computational algorithms used. 
These aspects can complicate the process of standardization 
of the method for MRD detection.
Recently Onecha et al60 explored the possibility of using 
deep sequencing MRD approach. They analyzed 190 patients 
affected by AML. A total of 211 (80%) single nucleotide 
variations and 46 (20%) indels were detected using the NGS 
custom panel. They followed the aberrations during follow-
up with the same approach and were able to demonstrate 
that MRD status (MRD levels >0.1%) at post-induction was 
associated with a significantly lower rate of OS (33% vs 
78%), while MRD-positive status after induction chemo-
therapy (MRD levels >0.025%) was associated with shorter 
OS (33% vs 81%) and significantly shorter DFS.
Levis et al61 recently published a sensitive and specific 
MRD assay for FLT3-ITD mutations using NGS. They 
demonstrated a relationship between the mutation burden, 
as detected by their assay, and OS.
Conclusion
In acute leukemias, the detection of MRD is highly infor-
mative of the outcome of therapies, including HSCTs. The 
majority of the studies on MRD reported data based on MFC 
and real-time qPCR. Many attempts are ongoing to improve 
the sensitivity and to standardize the currently available 
techniques. This aspect is important to reach a common 
agreement on the threshold of MRD that triggers therapeutic 
decisions. New molecular targets are under investigation with 
encouraging results. Furthermore, the availability of new 
molecular targeted drugs that can potentially fully eradicate 
the residual small clones stimulates the interest in the detec-
tion of residual leukemic cells. New promising approaches 
are on the horizon to enlarge the spectrum of patients who 
can be monitored for the persistence of leukemic clones, 
including NGS.
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